Integrated Mathematical Oncology Department Metrics

View the clinical trials, grants and publications from the Department of Integrated Mathematical Oncology.

Clinical Trials
CLINICAL TRIAL 19137
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Condition: Genitourinary
Intervention: Abiraterone acetate (); Olaparib (Lynparza); Zytiga (Abiraterone acetate); prednisone ()

CLINICAL TRIAL 19867
A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)
Condition: Genitourinary
Intervention: BXCL701 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20094
EDRN Prostate MRI Biomarker Study and Reference Set
Condition: Multiple
Intervention:

CLINICAL TRIAL 20117
A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN5678 ()

CLINICAL TRIAL 20534
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Cabozantinib (XL 184)

CLINICAL TRIAL 21139
A Phase IIA Study of Sequential ("first strike, second strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate (); Apalutamide (); Decapeptyl SR (Triptorelin); Degarelix (); Eligard (Leuprolide); Enzalutamide (Xtandi); Leuprolide (); Relugolix (Orgovyx); Taxotere (docetaxel); Tislelizumab (); Triptorelin (); Zytiga (Abiraterone acetate); docetaxel (); goserelin acetate (Zoladex); prednisone ()

CLINICAL TRIAL 21266
Gut Metabolome-Can it be Developed As A Biomarker of Response to Immunotherapy in Metastatic Renal Cell Cancer
Condition: Genitourinary
Intervention:

Grants
  • Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments
    Sponsor: Vanderbilt University
    PI (MPI):Rejniak, K.
  • Multi-Scale Modeling of Bone Environment Responses to Metastatic Prostate Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Basanta Gutierrez, D.,PI (MPI):Lynch, C.
  • Eco-Evolutionary Dynamics of NSCLC to Immunotherapy: Response and Resistance
    Sponsor: Nat Institutes of Health
    PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.
  • Evolutionary multi-drug therapy for ER+ breast cancer
    Sponsor: Nat Institutes of Health
    PI:Anderson, A.
  • Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI (MPI):Gatenby, R.
  • Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI (MPI):Pilon-Thomas, S.
  • A clone's genomic stability as biomarker of its DNA-damage resilience
    Sponsor: Nat Institutes of Health
    PI:Andor, N.
  • Simulating the effect of photoimmunotherapy on the ovarian cancer immune ecosystem
    Sponsor: Ocala Royal Dames
    PI:Enderling, H.
  • Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
  • Developing mathematical model driven optimized recurrent glioblastoma therapies
    Sponsor: Nat Institutes of Health
    PI (Contact):Enderling, H.,PI (MPI):Sahebjam, S.
  • A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments
    Sponsor: Nat Institutes of Health
    PI:Andor, N.
  • Evolving, understanding and optimising novel Cancer therapies
    Sponsor: US Dept of Energy
    PI:Anderson, A.
  • Innovative mathematical oncology approaches to identify patient-specific biomarkers to personalize radiation therapy for breast cancer patients
    Sponsor: Jayne Koskinas & Ted Giovanis Foundation for Health Policy
    PI:Enderling, H.
Publications
  • Gardner A, de Mingo Pulido Á, Hänggi K, Bazargan S, Onimus A, Kasprzak A, Conejo-Garcia JR, Rejniak KA, Ruffell B. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization. J Immunother Cancer. 2022 Jan.10(1). Pubmedid: 34987021. Pmcid: PMC8734033.
  • Gabbutt C, Schenck RO, Weisenberger DJ, Kimberley C, Berner A, Househam J, Lakatos E, Robertson-Tessi M, Martin I, Patel R, Clark SK, Latchford A, Barnes CP, Leedham SJ, Anderson ARA, Graham TA, Shibata D. Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues. Nat Biotechnol. 2022 Jan. Pubmedid: 34980912.
  • Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson ARA, Saglam O, Conejo-Garcia JR. IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer. Cancer Res. 2021 Dec. Pubmedid: 34949671.
  • Phan TV, Wang G, Do TK, Kevrekidis IG, Amend S, Hammarlund E, Pienta K, Brown J, Liu L, Austin RH. It doesn't always pay to be fit: success landscapes. J Biol Phys. 2021 Dec.47(4):387-400. Pubmedid: 34709534. Pmcid: PMC8603993.
  • Chancellor S, Abbo L, Grasse B, Sakmar T, Brown JS, Scheel D, Santymire RM. Determining the effectiveness of using dermal swabs to evaluate the stress physiology of laboratory cephalopods: A preliminary investigation. Gen Comp Endocrinol. 2021 Dec.314:113903. Pubmedid: 34529999.
  • Enderling H. Mathematical oncology: A new frontier in cancer biology and clinical decision making: Comment on "Improving cancer treatments via dynamical biophysical models" by M. Kuznetsov, J. Clairambault & V. Volpert. Phys Life Rev. 2021 Nov. Pubmedid: 34857476.
  • Zahid MU, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization. J Pers Med. 2021 Nov.11(11). Pubmedid: 34834476. Pmcid: PMC8622616.
  • Pasetto S, Enderling H, Gatenby RA, Brady-Nicholls R. Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer. Bull Math Biol. 2021 Nov.84(1):2. Pubmedid: 34797430. Pmcid: PMC8604892.
  • Andor N, Altrock PM, Jain N, Gomes AP. Tipping cancer cells over the edge: the context-dependent cost of high ploidy. Cancer Res. 2021 Nov. Pubmedid: 34785577.
  • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
  • Zahid MU, Mohsin N, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model. Int J Radiat Oncol Biol Phys. 2021 Nov.111(3):693-704. Pubmedid: 34102299. Pmcid: PMC8463501.
  • Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2021 Oct.11(1):20219. Pubmedid: 34642366. Pmcid: PMC8511136.
  • Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. Neoplasia. 2021 Sep.23(9):851-858. Pubmedid: 34298234. Pmcid: PMC8322456.
  • Kareva I, Luddy KA, O'Farrelly C, Gatenby RA, Brown JS. Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?. Front Immunol. 2021 Aug.12:668221. Pubmedid: 34531851. Pmcid: PMC8438324.
  • Cassidy T, Nichol D, Robertson-Tessi M, Craig M, Anderson ARA. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLoS Comput Biol. 2021 Aug.17(8):e1009348. Pubmedid: 34460809. Pmcid: PMC8432806.
  • Dujon AM, Capp JP, Brown JS, Pujol P, Gatenby RA, Ujvari B, Alix-Panabières C, Thomas F. Is There One Key Step in the Metastatic Cascade?. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359593. Pmcid: PMC8345184.
  • Kingsley JL, Costello JR, Raghunand N, Rejniak KA. Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations. PLoS Comput Biol. 2021 Jul.17(7):e1009206. Pubmedid: 34310608. Pmcid: PMC8341701.
  • Liu J, Hormuth DA, Davis T, Yang J, McKenna MT, Jarrett AM, Enderling H, Brock A, Yankeelov TE. A time-resolved experimental-mathematical model for predicting the response of glioma cells to single-dose radiation therapy. Integr Biol (Camb). 2021 Jul.13(7):167-183. Pubmedid: 34060613. Pmcid: PMC8271006.
  • Suveges S, Chamseddine I, Rejniak KA, Eftimie R, Trucu D. Collective Cell Migration in a Fibrous Environment: A Hybrid Multiscale Modelling Approach. Front Appl Math Stat. 2021 Jun.7. Pubmedid: 34322539. Pmcid: PMC8315487.
  • Messan MR, Damaghi M, Freischel A, Miao Y, Brown J, Gillies R, Wallace D. Predicting the results of competition between two breast cancer lines grown in 3-D spheroid culture. Math Biosci. 2021 Jun.336:108575. Pubmedid: 33757835.
  • Pasetto S, Gatenby RA, Enderling H. Bayesian Framework to Augment Tumor Board Decision Making. JCO Clin Cancer Inform. 2021 May.5:508-517. Pubmedid: 33974446. Pmcid: PMC8240793.
  • Dujon AM, Aktipis A, Alix-Panabières C, Amend SR, Boddy AM, Brown JS, Capp JP, DeGregori J, Ewald P, Gatenby R, Gerlinger M, Giraudeau M, Hamede RK, Hansen E, Kareva I, Maley CC, Marusyk A, McGranahan N, Metzger MJ, Nedelcu AM, Noble R, Nunney L, Pienta KJ, Polyak K, Pujol P, Read AF, Roche B, Sebens S, Solary E, Staňková K, Swain Ewald H, Thomas F, Ujvari B. Identifying key questions in the ecology and evolution of cancer. Evol Appl. 2021 Apr.14(4):877-892. Pubmedid: 33897809. Pmcid: PMC8061275.
  • West J, Schenck RO, Gatenbee C, Robertson-Tessi M, Anderson ARA. Normal tissue architecture determines the evolutionary course of cancer. Nat Commun. 2021 Apr.12(1):2060. Pubmedid: 33824323. Pmcid: PMC8024392.
  • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
  • Lo CH, Baratchart E, Basanta D, Lynch CC. Computational modeling reveals a key role for polarized myeloid cells in controlling osteoclast activity during bone injury repair. Sci Rep. 2021 Mar.11(1):6055. Pubmedid: 33723343. Pmcid: PMC7961065.
  • Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer. 2021 Mar.7(1):26. Pubmedid: 33707440. Pmcid: PMC7952601.
  • Pressley M, Gallaher JA, Brown JS, Tomaszewski MR, Borad P, Damaghi M, Gillies RJ, Whelan CJ. Cycling hypoxia selects for constitutive HIF stabilization. Sci Rep. 2021 Mar.11(1):5777. Pubmedid: 33707510. Pmcid: PMC7952589.
  • Freischel AR, Damaghi M, Cunningham JJ, Ibrahim-Hashim A, Gillies RJ, Gatenby RA, Brown JS. Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. Sci Rep. 2021 Mar.11(1):4908. Pubmedid: 33649456. Pmcid: PMC7921689.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Miroshnychenko D, Baratchart E, Ferrall-Fairbanks MC, Velde RV, Laurie MA, Bui MM, Tan AC, Altrock PM, Basanta D, Marusyk A. Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. Nat Ecol Evol. 2021 Mar.5(3):379-391. Pubmedid: 33462489.
  • Tomaszewski MR, Dominguez-Viqueira W, Ortiz A, Shi Y, Costello JR, Enderling H, Rosenberg SA, Gillies RJ. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy. Nmr Biomed. 2021 Mar.34(3):e4454. Pubmedid: 33325086.
  • Massey SC, Whitmire P, Doyle TE, Ippolito JE, Mrugala MM, Hu LS, Canoll P, Anderson ARA, Wilson MA, Fitzpatrick SM, McCarthy MM, Rubin JB, Swanson KR. Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma. Cancer Lett. 2021 Feb.498:178-187. Pubmedid: 33130315. Pmcid: PMC8409250.
  • Strobl MAR, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown JS, Gatenby RA, Maini PK, Anderson ARA. Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Res. 2021 Feb.81(4):1135-1147. Pubmedid: 33172930. Pmcid: PMC8455086.
  • Pienta KJ, Hammarlund EU, Brown JS, Amend SR, Axelrod RM. Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proc Natl Acad Sci U S A. 2021 Feb.118(7). Pubmedid: 33504594. Pmcid: PMC7896294.
  • Araujo A, Cook LM, Frieling JS, Tan W, Copland JA, Kohli M, Gupta S, Dhillon J, Pow-Sang J, Lynch CC, Basanta D. Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33567529. Pmcid: PMC7915310.
  • Kim E, Brown JS, Eroglu Z, Anderson ARA. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33669315. Pmcid: PMC7920057.